James Dentzer

EIDP, Inc. engages in the provision of science-based products and services. It operates through the Seed and Crop Protection segments. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms around the world. The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The company was founded by Eleuthere Irenee du Pont in 1802 and is headquartered in Indianapolis, IN.

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Valeritas, Inc. engages in the development and commercialization of drug delivery solutions for the treatment of diabetes. Its product, V-Go wearable insulin delivery device, which enables patients to closely mimic the body’s normal physiologic pattern of insulin delivery by using one type of insulin at a continuous preset basal rate over a 24-hour period and provides on-demand bolus dosing for meals and snacks. The company was founded on August 2, 2006 and is headquartered in Bridgewater, NJ.